Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 15716549.
- Also identified by PMC identifier 1739570.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Efficacy and safety of long term use of FK506 (2-4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no serious side effects.
Medical subject headings
- Immunosuppressive Agents
- Myasthenia Gravis
- Tacrolimus